Scrip
Acute heart failure data for Corthera's relaxin data "probably too good to be true"
30 March 2009
Alex Shimmings
The US biopharmaceutical company Corthera (formerly BAS Medical) is set to take its lead product, a recombinant version of the human hormone relaxin, into Phase III by the end of this year on the back of highly promising Phase IIb data in acute heart failure (AHF).
The study, Pre-RELAX-AHF, found...
Please Login to read the full article.
30 March 2009
Alex Shimmings
The study, Pre-RELAX-AHF, found...
Please Login to read the full article.
RELATED CONTENT
NEWS
- Medicines Company's halted CHAMPION trial failures prompt further studies
- Celladon to push heart failure gene therapy into Phase III on positive mid-stage data
- Price cuts have little effect on Orion's six-month sales
- US FDA advisors back AstraZeneca's Brilinta for thrombotic events
COMMENT
Other Informa Comment
FEATURES
- Face to Face with Sandoz's "growth guy" Jeff George
- Face-to-Face: Asia-Pacific emerging as the clinical trial hotspot
EVENTS
01 January 1970
London, UK
01 January 1970
San Diego, US
01 January 1970
Providence, Rhode Island, and San Francisco, California
JOB OF THE WEEK
Promote your vacancy here
